01:10 PM EST, 11/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target price of $310, valuing the shares at 9.1x our newly introduced 2027 EPS estimate of $33.90 and at 10x our 2026 EPS estimate of $30.85 (cut today by $2.18), versus the shares' one-year average forward multiple of 10x and the peer group average of 14.8x. We keep our 2025 EPS estimate of $29.67 after Q3 reported EPS of $7.83 beat our $7.79 EPS estimate. However, we lower our Q4 EPS estimate by a like amount to $7.90 from $7.94. We forecast revenue growth of just over 8% in 2025, moderating to a rise of 6% and 6.2% in 2026 and 2027, respectively. Currently trading at 8.6x our 2026 EPS estimate and yielding 2.3%, we view the share as undervalued versus peer and historical averages. We think CI is relatively well positioned within its peer group given its more limited exposure to federal government spend, with approximately 67% of its premium revenue from marketplace plans in 2024, which we think will grow given its Medicare business divestiture.